References
- García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016 Aug;36(4):355–371.
- Narasimhan M, Pae CU, Masand N, et al. Partial compliance with antipsychotics and its impact on patient outcomes. Intl J Psychiatry Clin Pract. 2007;11(2):102–111.
- Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007 Sep;58(9):1187–1192.
- Ershad Sarabi R, Sadoughi F, Jamshidi Orak R, et al. The effectiveness of mobile phone text messaging in improving medication adherence for patients with chronic diseases: a systematic review. Iran Red Crescent Med J. 2016 Apr 30;18(5):e25183.
- Kauppi K, Välimäki M, Hätönen HM, et al. Information and communication technology based prompting for treatment compliance for people with serious mental illness. Cochrane Database Syst Rev. 2014 Jun 17;(6):CD009960
- Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147–154.
- Mattila T, Koeter M, Wohlfarth T, et al. The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials. Eur Neuropsychopharmacol. 2017 Jan;27(1):82–86.
- Wade M, Tai S, Awenat Y, et al. A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev. 2016 Oct;28(51):75–95.
- Masand PS, Narisimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006;1(1):47–56.
- Available from: http://www.healthyplace.com/blogs/yourmentalhealth/2013/04/03/nonadherence-to-antipsychotics-in-schizophrenia-the-hidden-enemy/
- Available from: http://www.pmlive.com/pharma_news/things_can_only_get_better_1037040
- Masand PS. Differential pharmacology of atypical antipsychotics: clinical implications. Am J Health Syst Pharm. 2007;64(Suppl 1):SS3SS5.
- Masand PS, Gupta S. Quality of life issues associated with antipsychotic-induced weight gain. Expert Rev Pharmacoeconomics Outcomes Res. 2003;3:651–659.
- Masand PS, Tharwani HM, Patkar AA. Polypharmacy in schizophrenia. Intl J Psychiatry Clin Pract. 2006;10(4):258–263.
- Buckley PF, Schooler NR, Goff DC, et al.; PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar;41(2):449–459.
- Buckley PF, Schooler NR, Goff DC, et al. Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study. Psychiatr Serv. 2016 Dec 1;67(12):1370–1372.
- Bäuml J, Pitschel-Walz G, Volz A, et al. Psychoeducation improves compliance and outcome in schizophrenia without an increase of adverse side effects: a 7-year follow-up of the munich PIP-study. Schizophr Bull. 2016 Jul;42(Suppl 1):S62S70.
- Danzer G, Rieger SM. Improving medication adherence for severely mentally ill adults by decreasing coercion and increasing cooperation. Bull Menninger Clin. 2016 Winter;80(1):30–48. PMID: 27028337.
- Gray R, Bressington D, Ivanecka A, et al. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016 Apr 6;16:90. Review.
- Weiden PJ. Redefining medication adherence in the treatment of schizophrenia: how current approaches to adherence lead to misinformation and threaten therapeutic relationships. Psychiatr Clin North Am. 2016 Jun;39(2):199–216.
- Han C, Wang SM, Lee SJ, et al. Dilemma for enhancing psychiatrists’ adherence to guideline (evidence)-based practice. Expert Rev Neurother. 2013 Jul;13(7):751–754.
- Masand PS, Pae CU. Cognitive dysfunction in psychiatric illness: a neglected domain. J Clin Psychiatry. 2015 Mar;76(3):e375–7.
- Treisman GJ, Jayaram G, Margolis RL, et al. Perspectives on the use of ehealth in the management of patients with schizophrenia. J Nerv Ment Dis. 2016 Aug;204(8):620–629.
- Firth J, Torous J. Smartphone apps for schizophrenia: a systematic review. JMIR Mhealth Uhealth. 2015 Nov 6;3(4):e102.
- Lincoln TM, Jung E, Wiesjahn M, et al. The impact of negative treatment experiences on persistent refusal of antipsychotics. Compr Psychiatry. 2016;70:165–173.
- Peters-Strickland T, Pestreich L, Hatch A, et al. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatr Dis Treat. 2016 Oct 11;12:2587–2594.